Results 141 to 150 of about 14,611,152 (262)

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem   +5 more
wiley   +1 more source

TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk

open access: yesHepatology, EarlyView., 2022
The systematic approach in elucidating the gain‐of‐function (GOF) roles of TP53 mutations in early liver carcinogenesis. Unique downstream targets of TP53 L3 mutations were identified from chormatin immunoprecipitation sequencing in HCC cell lines, followed by a series of validation assays to substantiate the exclusive transcriptional regulations ...
Yin Kau Lam   +10 more
wiley   +1 more source

Factors associated with hepatitis B virus infection among pregnant women attending antenatal clinic in Western Area Urban District, Sierra Leone

open access: yesWomen's Health
Background: Hepatitis B virus infection remains a global health concern, particularly in resource-constrained countries such as Sierra Leone. Understanding the risk factors for hepatitis B virus among pregnant women can guide public health initiatives ...
Solomon Aiah Sogbeh   +7 more
doaj   +1 more source

Hepatitis B vaccination in the Columbian Amazon : effectiveness and factors influencing vaccine coverage [PDF]

open access: yes
A vaccination coverage survey was carried out in the Colombian Amazon, a former high endemic area for hepatitis B, involving 3573 children less than II years old. It was carried out in Leticia, Puerto Narifio, and Araracuara, both urban and rural areas.
De La Hoz, Fernando
core   +1 more source

Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno   +13 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening

open access: yesHepatology Communications, EarlyView., 2022
Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff   +17 more
wiley   +1 more source

Incidence of Hepatitis B and HIV Virus at Cadaver of IV Drug Abusers in Tehran [PDF]

open access: yes
Injection drug use has been the most growing rout of drug abuse in Iran in the past decade and it has been responsible for the transmission of HIV virus in more than two third of cases.
اخلاقی, میترا   +6 more
core  

Determinants of hepatitis C virus clinical outcomes [PDF]

open access: yes
Hepatitis C VIruS (HCY) infection is characterized by a broad spectrum of clinical outcomes. An estimated 14%-46% of individuals exposed to HCY are able to clear the virus, while the other portion develops chronic ...
Yee, Leland Jonathan
core   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy